E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Major Depressive Disorder |
Trastorno depresivo mayor |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Psychiatry and Psychology [F] - Mental Disorders [F03] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10057840 |
E.1.2 | Term | Major depression |
E.1.2 | System Organ Class | 10037175 - Psychiatric disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Evaluation of the long-term safety and tolerability of vortioxetine in child and adolescent patients with a Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5?) diagnosis of MDD. |
Evaluación de la seguridad y tolerabilidad a largo plazo de vortioxetina en niños y adolescentes con Manual Diagnóstico y Estadístico de los Trastornos Mentales, 5ª edición (DSM-5TM) diagnosticados de TDM |
|
E.2.2 | Secondary objectives of the trial |
Evaluation of the long-term effectiveness of flexible doses of vortioxetine in a range of 5 mg/day to 20 mg/day on: - depressive symptoms - clinical global impression - cognitive function - functionality |
Evaluación de la efectividad a largo plazo de dosis flexibles de vortioxetina en un intervalo de entre 5 mg/día y 20 mg/día sobre: ? los síntomas depresivos; ? la impresión clínica global; ? la función cognitiva; ? la funcionalidad. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- The patient is a male or female child aged > =7 and <12 years or an adolescent aged > =12 and <=18 years in the lead-in study (12709A and 12710A). - The patient must have completed Study 12709A or 12710A (Visit 12, Completion Visit) immediately prior to enrolment into this extension study. - The patient had a primary diagnosis of MDD at entry in study 12709A or 12710A, diagnosed according to DSM-5?. - The patient is indicated for long-term treatment with vortioxetine according to the clinical opinion of the Investigator. |
- Pacientes, niños o niñas, de entre > =7 y <12 años o adolescentes de entre > =12 y <=18 años de edad en el estudio introductorio (12709A and 12710A). - Pacientes que hayan finalizado el estudio 12709A o 12710A (visita 12, visita de finalización) inmediatamente antes de su inclusión en este estudio de extensión. - Pacientes con un diagnóstico primario de trastorno depresivo mayor (TDM) en el momento de su entrada al estudio 12709A o 12710A, diagnosticado según el DSM-5?. - Pacientes para los que está indicado el tratamiento a largo plazo con vortioxetina, según la opinión clínica del investigador. |
|
E.4 | Principal exclusion criteria |
- The patient has been diagnosed with another psychiatric disorder (for example mania, bipolar disorder, schizophrenia or any psychotic disorder) during study 12709A or 12710A. - The patient has an attention-deficit/hyperactivity disorder (ADHD) that requires a pharmacological treatment other than a stimulant medication. |
- Pacientes con diagnóstico de otro trastorno psiquiátrico (por ejemplo, manía, trastorno bipolar, esquizofrenia o cualquier trastorno psicótico) durante el estudio 12709A o 12710A. - Pacientes con trastorno por déficit de atención o hiperactividad (TDAH) que requieran un tratamiento farmacológico que no sea una medicación estimulante. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Safety: Safety evaluation based on adverse events, paediatric adverse event rating scale (PAERS), clinical safety laboratory tests (including reproductive hormones), vital signs, weight, height, Tanner score, menstrual cycle, ECG, and C-SSRS. |
Seguridad: Evaluaciones de seguridad basadas en acontecimientos adversos, escala de puntuación de acontecimientos adversos pediátricos (PAERS), pruebas analíticas de seguridad clínica (incluidas las de las hormonas reproductivas), constantes vitales, peso, estatura , puntuación de Tanner, ciclo menstrual , ECG y C-SSRS. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Throughout the study |
Durante todo el estudio |
|
E.5.2 | Secondary end point(s) |
- Change in Children Depression Rating Scale - Revised version (CDRS-R) total score - Number of relapses (CDRS-R > =40 with a history of 2 weeks of clinical deterioration) - Loss of remission (CDRS-R <28 with a history of 2 weeks of clinical deterioration) - Change in Clinical Global Impression - Severity of Illness (CGI-S) score - Clinical Global Impression - Global Improvement (CGI-I) score - Children (7-11 years): Change in Behaviour Rating Inventory of Executive Function (BRIEF) using the Global Executive Composite score - Children (7-11 years): Change in BRIEF using the Metacognition Index - Adolescents (12-18 years): Change in Behaviour Rating Inventory of Executive Function - Self-report version (BRIEF-SR) using the Global Executive Composite score - Adolescents (12-18 years): Change in BRIEF-SR using the Metacognition Index - Change in Children?s Global Assessment Scale (CGAS) score - Change in in Pediatric Quality of Life Inventory Present Functioning Visual Analogue Scales (PedsQL VAS) score |
- Cambio en la puntuación total de la escala de puntuación de la depresión en niños, versión revisada (CDRS-R) - Número de recidivas (CDRS-R > =40 con antecedentes de 2 semanas de deterioro clínico) - Pérdida de remisión (CDRS-R <28 con antecedentes de 2 semanas de deterioro clínico) - Cambio en la puntuación de la impresión clínica global: gravedad de la enfermedad (CGI-S) - Puntuación de la impresión clínica global: mejoría global (CGI-I) - Niños (7 a 11 años): cambio en el inventario de puntuación conductual de la función ejecutiva (BRIEF) usando la puntuación compuesta global de la función ejecutiva - Niños (7 a 11 años): cambio en BRIEF usando el índice de metacognición - Adolescentes (12 a 18 años): cambio en el inventario de puntuación conductual de la función ejecutiva autoadministrado (BRIEF-SR) usando la puntuación compuesta global de la función ejecutiva - Adolescentes (12 a 18 años): cambio en BRIEF-SR usando el índice de metacognición - Cambio en la puntuación de la escala de evaluación global del niño (CGAS) - Cambio en la puntuación de las escalas visuales analógicas (EVA) de funcionamiento actual del PedsQL |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Throughout the study |
Durante todo el estudio |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 60 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Austria |
Belgium |
Bulgaria |
Canada |
Denmark |
Estonia |
Finland |
France |
Germany |
Hungary |
Ireland |
Italy |
Latvia |
Lithuania |
Mexico |
Netherlands |
Poland |
Romania |
Russian Federation |
Serbia |
Slovakia |
South Africa |
Spain |
Sweden |
Ukraine |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS |
LVLS (última visita del último paciente) |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 11 |
E.8.9.1 | In the Member State concerned days | 29 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 11 |
E.8.9.2 | In all countries concerned by the trial days | 29 |